Sunday 25 March 2018

Discover Market study on PANCREATIC CANCER Industry - Pipeline Review, H1 2017


Overview
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.
Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects. 

Table of Contents 
Introduction 13
Pancreatic Cancer - Overview 14
Pancreatic Cancer - Therapeutics Development 15
Pancreatic Cancer - Therapeutics Assessment 80
Pancreatic Cancer - Companies Involved in Therapeutics Development 117
Pancreatic Cancer - Drug Profiles 275
Pancreatic Cancer - Dormant Projects 1987
Pancreatic Cancer - Discontinued Products 2006
Pancreatic Cancer - Product Development Milestones 2011
Appendix 2027
List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 
Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

No comments:

Post a Comment